Technical Analysis for RARE - Ultragenyx Pharmaceutical Inc.

Grade Last Price % Change Price Change
grade F 42.57 -1.84% -0.80
RARE closed down 1.84 percent on Friday, September 20, 2019, on 3.03 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical RARE trend table...

Date Alert Name Type % Chg
Volume Surge Other 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
NR7 Range Contraction -1.84%
NR7-2 Range Contraction -1.84%
Stochastic Reached Oversold Weakness -2.23%
Wide Bands Range Expansion -2.23%

Older signals for RARE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Rare Diseases Enzyme Replacement Therapy Biologics Rare And Ultra Rare Diseases
Is RARE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 90.98
52 Week Low 37.44
Average Volume 530,707
200-Day Moving Average 57.5888
50-Day Moving Average 54.8018
20-Day Moving Average 47.442
10-Day Moving Average 43.804
Average True Range 2.613
ADX 36.37
+DI 9.9474
-DI 30.1579
Chandelier Exit (Long, 3 ATRs ) 51.501
Chandelier Exit (Short, 3 ATRs ) 49.349
Upper Bollinger Band 56.563
Lower Bollinger Band 38.321
Percent B (%b) 0.23
BandWidth 38.451161
MACD Line -3.6372
MACD Signal Line -3.5918
MACD Histogram -0.0455
Fundamentals Value
Market Cap 1.81 Billion
Num Shares 42.6 Million
EPS -6.74
Price-to-Earnings (P/E) Ratio -6.32
Price-to-Sales 16800.34
Price-to-Book 4.53
PEG Ratio -0.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 46.22
Resistance 3 (R3) 46.49 45.54 45.61
Resistance 2 (R2) 45.54 44.62 45.41 45.40
Resistance 1 (R1) 44.06 44.04 43.59 43.79 45.20
Pivot Point 43.11 43.11 42.88 42.98 43.11
Support 1 (S1) 41.63 42.19 41.16 41.36 39.94
Support 2 (S2) 40.68 41.61 40.55 39.74
Support 3 (S3) 39.20 40.68 39.53
Support 4 (S4) 38.93